4 USD
+0.12 (+3.09%)
4.08 USD
+0.08 (+2%)
We assign a fundamental rating of 4 out of 10 to CTMX. CTMX was compared to 530 industry peers in the Biotechnology industry. CTMX has an excellent financial health rating, but there are some minor concerns on its profitability. CTMX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CTMX was profitable.
In the past year CTMX has reported a negative cash flow from operations.
In the past 5 years CTMX reported 4 times negative net income.
CTMX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 17.70%, CTMX belongs to the best of the industry, outperforming 96.05% of the companies in the same industry.
CTMX has a better Return On Equity (26.09%) than 97.37% of its industry peers.
CTMX has a better Return On Invested Capital (15.67%) than 96.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.7% | ||
| ROE | 26.09% | ||
| ROIC | 15.67% |
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of CTMX (24.66%) is better than 94.55% of its industry peers.
CTMX has a Operating Margin of 20.46%. This is amongst the best in the industry. CTMX outperforms 94.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.46% | ||
| PM (TTM) | 24.66% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CTMX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, CTMX has more shares outstanding
The number of shares outstanding for CTMX has been increased compared to 5 years ago.
CTMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 3.98 indicates that CTMX is not in any danger for bankruptcy at the moment.
CTMX has a Altman-Z score of 3.98. This is in the better half of the industry: CTMX outperforms 70.49% of its industry peers.
There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.98 |
ROIC/WACC1.78
WACC8.8%
2.3 Liquidity
A Current Ratio of 3.64 indicates that CTMX has no problem at all paying its short term obligations.
CTMX's Current ratio of 3.64 is in line compared to the rest of the industry. CTMX outperforms 43.42% of its industry peers.
A Quick Ratio of 3.64 indicates that CTMX has no problem at all paying its short term obligations.
CTMX's Quick ratio of 3.64 is in line compared to the rest of the industry. CTMX outperforms 45.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.64 | ||
| Quick Ratio | 3.64 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 140.59% over the past year.
CTMX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.26%.
CTMX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.15% yearly.
EPS 1Y (TTM)140.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.57%
Revenue 1Y (TTM)-10.26%
Revenue growth 3Y54.7%
Revenue growth 5Y19.15%
Sales Q2Q%-82.16%
3.2 Future
Based on estimates for the next years, CTMX will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.96% on average per year.
The Revenue is expected to grow by 0.34% on average over the next years.
EPS Next Y-103.4%
EPS Next 2Y-73.45%
EPS Next 3Y-45.95%
EPS Next 5Y-22.96%
Revenue Next Year-31.15%
Revenue Next 2Y-41.75%
Revenue Next 3Y-27.37%
Revenue Next 5Y0.34%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
CTMX is valuated reasonably with a Price/Earnings ratio of 9.76.
Based on the Price/Earnings ratio, CTMX is valued cheaper than 97.74% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.39, CTMX is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for CTMX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.76 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CTMX is valued cheaply inside the industry as 94.36% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 17.32 |
4.3 Compensation for Growth
A cheap valuation may be justified as CTMX's earnings are expected to decrease with -45.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-73.45%
EPS Next 3Y-45.95%
5. Dividend
5.1 Amount
CTMX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
4
+0.12 (+3.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners77.94%
Inst Owner Change3.03%
Ins Owners0.53%
Ins Owner Change-2.89%
Market Cap677.76M
Revenue(TTM)113.63M
Net Income(TTM)28.02M
Analysts84.29
Price Target7.21 (80.25%)
Short Float %11.44%
Short Ratio5.81
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.22%
Min EPS beat(2)-74.27%
Max EPS beat(2)98.72%
EPS beat(4)3
Avg EPS beat(4)88.28%
Min EPS beat(4)-74.27%
Max EPS beat(4)215.22%
EPS beat(8)7
Avg EPS beat(8)121.73%
EPS beat(12)10
Avg EPS beat(12)96.64%
EPS beat(16)11
Avg EPS beat(16)69.24%
Revenue beat(2)1
Avg Revenue beat(2)-12.98%
Min Revenue beat(2)-49.71%
Max Revenue beat(2)23.76%
Revenue beat(4)3
Avg Revenue beat(4)32.06%
Min Revenue beat(4)-49.71%
Max Revenue beat(4)92.34%
Revenue beat(8)7
Avg Revenue beat(8)44.02%
Revenue beat(12)10
Avg Revenue beat(12)36.04%
Revenue beat(16)10
Avg Revenue beat(16)9.74%
PT rev (1m)15.12%
PT rev (3m)22.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-30.76%
EPS NY rev (1m)-144.17%
EPS NY rev (3m)-175.58%
Revenue NQ rev (1m)-20.71%
Revenue NQ rev (3m)-34.6%
Revenue NY rev (1m)-10.16%
Revenue NY rev (3m)-10.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.76 | ||
| Fwd PE | N/A | ||
| P/S | 5.96 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.31 | ||
| P/tB | 6.4 | ||
| EV/EBITDA | 17.32 |
EPS(TTM)0.41
EY10.25%
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.67
BVpS0.63
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.7% | ||
| ROE | 26.09% | ||
| ROCE | 19.83% | ||
| ROIC | 15.67% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 20.46% | ||
| PM (TTM) | 24.66% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 7.74% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.64 | ||
| Quick Ratio | 3.64 | ||
| Altman-Z | 3.98 |
F-Score5
WACC8.8%
ROIC/WACC1.78
Cap/Depr(3y)42.33%
Cap/Depr(5y)55.65%
Cap/Sales(3y)1.42%
Cap/Sales(5y)2.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)140.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.57%
EPS Next Y-103.4%
EPS Next 2Y-73.45%
EPS Next 3Y-45.95%
EPS Next 5Y-22.96%
Revenue 1Y (TTM)-10.26%
Revenue growth 3Y54.7%
Revenue growth 5Y19.15%
Sales Q2Q%-82.16%
Revenue Next Year-31.15%
Revenue Next 2Y-41.75%
Revenue Next 3Y-27.37%
Revenue Next 5Y0.34%
EBIT growth 1Y246.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.27%
EBIT Next 3Y-120.2%
EBIT Next 5YN/A
FCF growth 1Y-99.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-103.53%
OCF growth 3YN/A
OCF growth 5YN/A
CYTOMX THERAPEUTICS INC / CTMX FAQ
What is the fundamental rating for CTMX stock?
ChartMill assigns a fundamental rating of 4 / 10 to CTMX.
What is the valuation status of CYTOMX THERAPEUTICS INC (CTMX) stock?
ChartMill assigns a valuation rating of 3 / 10 to CYTOMX THERAPEUTICS INC (CTMX). This can be considered as Overvalued.
How profitable is CYTOMX THERAPEUTICS INC (CTMX) stock?
CYTOMX THERAPEUTICS INC (CTMX) has a profitability rating of 4 / 10.
How financially healthy is CYTOMX THERAPEUTICS INC?
The financial health rating of CYTOMX THERAPEUTICS INC (CTMX) is 7 / 10.